ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Intermountain Health Study Shows How to Best Reduce Need for Blood Transfusions in Premature Babies

The Intermountain Health study examined the dosage and frequency of administering darbepoetin

(PRUnderground) April 25th, 2025

A new study published in the Journal of Perinatology is helping premature babies avoid blood transfusions, thanks to new research and collaboration between researchers at Intermountain Health and the University of Utah.

Timothy Bahr, MD, an Intermountain Health neonatologist and researcher, collaborated with Robert Christensen, MD, and Robin Ohls, MD, from University of Utah Health, to explore the dosage and frequency needed of a medication called darbepoetin (darbe), which boosts red blood cell production in premature infants.

Premature babies often suffer from low red blood cell counts (anemia), which can contribute to various complications such as developmental delays and difficulty breathing.

Subcutaneous injections of darbe have been used to effectively treat anemia of prematurity and boost red blood cell production in premature infants, to help decrease the need for red blood cell transfusions in the United States for the past 20 years.

The goal of the study was to refine the dosage and frequency of darbe to these vulnerable babies, so it provides optimal health benefits, along with the minimum necessary number of subcutaneous injections.

Dr. Bahr and his collaborators, who have been at the forefront of research on treatment for anemia in premature babies, conducted their study at Intermountain Medical Center in Murray and Intermountain Utah Valley Hospital in Provo.

The study tested two different dosing schedules: injections once a week and once every two weeks.

The results were promising.

“We found that while weekly doses of darbe increased red blood cell production slightly more, both schedules resulted in similar overall health outcomes for the babies,” said Dr. Bahr. “This means that giving Darbe every two weeks could be a viable option, reducing the number of injections these infants need.”

“Fewer injections can lead to a more comfortable experience for premature babies and their parents, and it also could potentially lower healthcare and pharmacy costs,” he added.

According to neonatologists, when darbe improves red blood cell counts to more normal levels in premature infants, they are less likely to need a blood transfusion.

Some preemies need only darbe injections, while more severe newborn patients may also need a blood transfusion to help them be more likely to survive their stay in a neonatal ICU.

“Transfusions can be done safely and can be lifesaving for preemies, but they do come with some risks. If we can reduce the need for blood transfusions in preemies, we can also reduce their risk of complications which can occur after a blood transfusion,” said Dr Bahr.

According to Dr. Bahr, the transfusion rate of premature infants in Intermountain Health neonatal ICUs is well below the national average.

Intermountain’s use of darbe and its ongoing research into best practices for the medication over the last 20 years are all part of an effort to reduce the number of transfusions preterm babies require.

“Eliminating unnecessary blood transfusions at Intermountain Health or ‘transfusion stewardship’ is much like our antibiotic stewardship efforts, which promote responsible use of antibiotics and reduces unnecessary use and enhances patient care and outcomes,” said Dr. Bahr.

“This research study’s findings offer a potential new approach to administering darbepoetin to premature babies, providing a balance between effective treatment and the comfort of fewer medical interventions,” said Elizabeth O’Brien, MD, senior medical director for neonatal health at Intermountain Health. “This is one of the many ways Intermountain is working to enhance the health and well-being of premature infants and provide more advanced and compassionate care for these very young and vulnerable patients.”

Intermountain Primary Children’s Hospital is home to the leading Level IV Neonatal ICU in the Mountain West, and Intermountain has 17 other hospitals (10 in Utah) with a neonatal ICU.

Providers at all 20 Intermountain Health hospitals with labor and delivery units in Utah have access to virtual neonatologists 24 hours a day, seven days a week. Intermountain Health is nationally recognized for the unique ability to provide this high-level of neonatal telemedicine to rural hospitals.

About Intermountain Health

Headquartered in Utah with locations in six states and additional operations across the western U.S., Intermountain Health is a not-for-profit system of 34 hospitals, approximately 400 clinics, medical groups with some 4,600 employed physicians and advanced care providers, a health plans division called Select Health with more than one million members, and other health services. Helping people live the healthiest lives possible, Intermountain is committed to improving community health and is widely recognized as a leader in transforming healthcare by using evidence-based best practices to consistently deliver high-quality outcomes at sustainable costs. For up-to-date information and announcements, please see the Intermountain Health newsroom at https://intermountainhealthcare.org/news.

The post Intermountain Health Study Shows How to Best Reduce Need for Blood Transfusions in Premature Babies first appeared on

Press Contact

Name: Lance Madigan
Phone: 801-442-3217
Email: Contact Us

Original Press Release.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.